Home > Insider Trading > Filing (0001179110-19-000867)

Filing Details

Accession Number:: 0001179110-19-000867
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-01-23 08:35:09
Reporting Period:: 2019-01-17

Accepted Time:: 2019-01-23 08:35:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1651561	Tabula Rasa Healthcare Inc.	TRHC	Services-Business Services, Nec (7389)	465726437

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1685833	H Calvin Knowlton	228 Strawbridge Drive Suite 100 Moorestown NJ 08057	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-01-17	2,924	$63.54	775,147	No	4	S	Indirect	Held by spouse.
Common Stock	Disposition	2019-01-17	3,396	$64.71	771,751	No	4	S	Indirect	Held by spouse.
Common Stock	Disposition	2019-01-17	400	$65.70	771,351	No	4	S	Indirect	Held by spouse.
Common Stock	Disposition	2019-01-17	1,080	$66.52	770,271	No	4	S	Indirect	Held by spouse.
Common Stock	Disposition	2019-01-17	200	$67.63	770,071	No	4	S	Indirect	Held by spouse.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Held by spouse.
No	4	S	Indirect	Held by spouse.
No	4	S	Indirect	Held by spouse.
No	4	S	Indirect	Held by spouse.
No	4	S	Indirect	Held by spouse.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	844,419	Direct
Common Stock	10,000	Indirect	Held by trust for children.
Common Stock	10,000	Indirect	Held by trust for children.

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Orsula V. Knowlton on May 15, 2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.12 to $64.10, inclusive. The reporting person undertakes to provide to Tabula Rasa HealthCare, Inc., any security holder of Tabula Rasa HealthCare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.31 to $65.15, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.31 to $66.12, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.37 to $66.92, inclusive.
The sales aggregated in Row 1 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sales aggregated in Row 2 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sales aggregated in Row 3 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sales aggregated in Row 4 of Table I are not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.
The sale in Row 5 of Table I is not matchable under Section 16(b) of the Securities Exchange Act of 1934 against purchases at lower prices by The reporting person on November 12, 2018 because such purchases were previously matched with sales on September 7, 2018 at higher sales prices, and The reporting person has already paid to Tabula Rasa Healthcare, Inc. the full amount of profit realized in connection with the previous short-swing transactions. Thus, no further disgorgement under Section 16(b) would result from the transactions disclosed herein.